These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 28187748

  • 1. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.
    J Ovarian Res; 2017 Feb 10; 10(1):9. PubMed ID: 28187748
    [Abstract] [Full Text] [Related]

  • 2. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ, Li HR, Cheng X, Bi R, Tu XY, Liu F, Chen LH.
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec 25; 52(12):835-843. PubMed ID: 29325268
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
    Zhang X, Guo G, Wang G, Zhao J, Wang B, Yu X, Ding Y.
    Mol Med Rep; 2015 Dec 25; 12(6):8021-31. PubMed ID: 26497752
    [Abstract] [Full Text] [Related]

  • 5. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma.
    Akashi H, Yachida N, Ueda H, Yamaguchi M, Yamawaki K, Tamura R, Suda K, Ishiguro T, Adachi S, Nagase Y, Ueda Y, Ueda M, Abiko K, Kagabu M, Baba T, Nakaoka H, Enomoto T, Murai J, Yoshihara K.
    Mol Cancer Ther; 2024 Jan 03; 23(1):106-116. PubMed ID: 37717249
    [Abstract] [Full Text] [Related]

  • 6. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B.
    BMC Cancer; 2014 Feb 11; 14():80. PubMed ID: 24512620
    [Abstract] [Full Text] [Related]

  • 7. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K, Fujimoto M, Kimura T, Naka T.
    Int J Cancer; 2009 Nov 15; 125(10):2316-22. PubMed ID: 19598262
    [Abstract] [Full Text] [Related]

  • 8. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T, Shibata K, Kajiyama H, Yamamoto E, Nawa A, Kikkawa F.
    J Clin Pathol; 2010 Nov 15; 63(11):962-6. PubMed ID: 20972242
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A, Sarian LO, Ferracini AC, Costa LBE, Mazzola PG, de Angelo Andrade L, Derchain S.
    Hum Pathol; 2019 Mar 15; 85():72-81. PubMed ID: 30447298
    [Abstract] [Full Text] [Related]

  • 10. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
    Hazama Y, Moriya T, Sugihara M, Sano R, Shiota M, Nakamura T, Shimoya K.
    Int J Gynecol Pathol; 2018 Nov 15; 37(6):516-524. PubMed ID: 29019869
    [Abstract] [Full Text] [Related]

  • 11. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C, Gao JC, Zhang PX, Zhang KN, Yang S, Kang TJ, Zhao HZ, Qi WJ, Zhang QP, Kong FD, Guan HW, Shi H.
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug 25; 55(8):529-534. PubMed ID: 32854477
    [Abstract] [Full Text] [Related]

  • 12. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
    BMC Cancer; 2014 Feb 22; 14():120. PubMed ID: 24559118
    [Abstract] [Full Text] [Related]

  • 13. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
    Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.
    Int J Oncol; 2015 Apr 22; 46(4):1573-81. PubMed ID: 25633807
    [Abstract] [Full Text] [Related]

  • 14. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T.
    Mol Cancer Res; 2015 Apr 22; 13(4):795-806. PubMed ID: 25519148
    [Abstract] [Full Text] [Related]

  • 15. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, Hirano H, Miyagi E.
    PLoS One; 2016 Apr 22; 11(10):e0165609. PubMed ID: 27798689
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S, Fritzsche F, Kristiansen G, Weichert W, Sehouli J, Braicu I, Dietel M, Denkert C.
    Virchows Arch; 2012 Aug 22; 461(2):109-16. PubMed ID: 22752467
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.